Clinical Drug Investigation

, Volume 16, Issue 6, pp 453–462 | Cite as

Selective Serotonin Reuptake Inhibitor Use in Primary Care

A 5-Year Naturalistic Study
  • John Donoghue



Objective: To investigate prescribing trends of selective serotonin reuptake inhibitors (SSRIs) during the course of the Defeat Depression Campaign (1992 to 1996).

Methods: This study utilised cross-sectional data on the prescribing of SSRIs for the treatment of depression from a large primary care database for the 5 consecutive years of the Defeat Depression Campaign, producing the largest study of SSRI use to date.

Results: A total of 93 600 prescriptions were issued for fluoxetine, paroxetine and sertraline, in 27 210 treatment episodes. Over the 5-year period, there was a five-fold increase in the number of prescriptions issued, and a four-fold increase in the number of patients treated, reflecting a trend for longer periods of treatment. Patients initiating treatment with fluoxetine were most likely and those initiating treatment with sertraline were least likely to complete 60, 90 and 120 consecutive days of treatment. Differences in dose patterns also emerged and were consistent throughout the study. Fluoxetine-treated patients were most likely to remain on the starting dose of 20mg daily, while large numbers of sertraline-treated patients received doses above the recommended dose of 50mg daily. These differences were not apparent from clinical trials, and this may be an artefact of trial design.

Conclusion: Differences in the doses prescribed may explain why sertraline-treated patients are less likely to complete an adequate course of antidepressant therapy. Longitudinal studies are required to evaluate fully the clinical significance of these findings.


Adis International Limited Fluoxetine Paroxetine Sertraline Selective Serotonin Reuptake Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ 1992; 305: 1198–202PubMedCrossRefGoogle Scholar
  2. 2.
    Klerman GL, Weissman MM. The course, morbidity, and costs of depression. Arch Gen Psychiatry 1992; 49: 831–4PubMedCrossRefGoogle Scholar
  3. 3.
    Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients: results from the medical outcomes study. JAMA 1989; 262: 914–9PubMedCrossRefGoogle Scholar
  4. 4.
    Hays RD, Wells KB, Sherbourne CD, et al. Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses. Arch Gen Psychiatry 1995; 52: 11–9PubMedCrossRefGoogle Scholar
  5. 5.
    Freeling PR, Tylee A. Depression in general practice. In: Paykel ES, editor. Handbook of affective disorders. Edinburgh: Churchill Livingstone, 1992Google Scholar
  6. 6.
    Song F, Freemantle N, Sheldon T, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683–7PubMedCrossRefGoogle Scholar
  7. 7.
    Anderson IM, Tomenson BM. The efficacy of selective serotonin reuptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994; 8: 238–49PubMedCrossRefGoogle Scholar
  8. 8.
    Hotopf M, Lewis G, Normand C. Are SSRIs a cost effective alternative to tricyclics? Br J Psychiatry 1996; 168: 404–9PubMedCrossRefGoogle Scholar
  9. 9.
    Donoghue JM, Tylee A, Wildgust HJ. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ 1996; 313: 861–2PubMedCrossRefGoogle Scholar
  10. 10.
    Finlay P. Selective serotonin reuptake inhibitors: pharmacological profiles and potential therapeutic distinctions. Ann Pharmacother 1994; 28: 1359–69Google Scholar
  11. 11.
    Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993; 15(3 Suppl.): 54–8Google Scholar
  12. 12.
    Donoghue JM. A comparison of prescribing patterns of selective serotonin reuptake inhibitors in the treatment of depression in primary care in the United Kingdom. J Serotonin Res 1995; 1: 47–51Google Scholar
  13. 13.
    Donoghue JM. Prescribing patterns of selective serotonin reuptake inhibitors in primary care: a naturalistic follow up study. J Serotonin Res 1996; 4: 267–70Google Scholar
  14. 14.
    Gregor KJ, Overhage JM, Coons SJ, et al. Selective serotonin re-uptake inhibitor dose titration in the naturalistic setting. Clin Ther 1994; 16:306–15PubMedGoogle Scholar
  15. 15.
    Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organisation. J Int Med Res 1995; 23: 395–412PubMedGoogle Scholar
  16. 16.
    Thompson D, Buesching D, Gregor KJ, et al. Patterns of antidepressant use and their relation to costs of care. Am J Manage Care 1996; 2: 1239–46Google Scholar
  17. 17.
    Montgomery SA, Bebbington P, Cowen P, et al. Guidelines for treating depressive illness with antidepressants: a statement from the British Association for Psychopharmacology. J Psychopharmacol 1993; 7: 19–23PubMedGoogle Scholar
  18. 18.
    Donoghue JM, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the United Kingdom. Br J Psychiatry 1996; 168: 164–8PubMedCrossRefGoogle Scholar
  19. 19.
    Dodd GK, Berti C. A critical appraisal of a naturalistic study to support cost effective prescribing patterns of selective serotonin reuptake inhibitors in primary care. J Serotonin Res 1997; 3: 169–72Google Scholar
  20. 20.
    Hylan TR, Crown WH, Meneades L, et al. Initial antidepressant selection and health care costs: a multivariate analysis. J Affect Disord 1998; 47: 71–9PubMedCrossRefGoogle Scholar
  21. 21.
    Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996; 38: 97–111PubMedCrossRefGoogle Scholar
  22. 22.
    Hotopf M, Lewis G, Normand C. Putting trials on trial — the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health 1997; 51: 354–8PubMedCrossRefGoogle Scholar
  23. 23.
    Lane RM. Incentive bias? [letter]. J Clin Psychiatry 1996; 57: 265–7PubMedGoogle Scholar
  24. 24.
    Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline safety and efficacy in major depression: a double blind fixed dose comparison with placebo. Biol Psychiatry 1995; 38: 592–602PubMedCrossRefGoogle Scholar
  25. 25.
    Preskorn SH, Lane RM. Sertraline 50mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995; 10: 129–41PubMedCrossRefGoogle Scholar
  26. 26.
    Nemeroff CB. Dr Nemeroff Replies [letter]. J Clin Psychiatry 1996; 57: 267–9Google Scholar
  27. 27.
    Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995; 56: 288–96PubMedGoogle Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Pharmacy DepartmentClatterbridge HospitalBebingtonEngland
  2. 2.School of Pharmacy and ChemistryLiverpool John Moores UniversityLiverpoolEngland

Personalised recommendations